TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05423327

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No Intervention
Description: Single blood draw
Study: NCT06018896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: For patients with baseline serum Vitamin C concentration \< 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
Study: NCT06073054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Research Pharmacist
Description: The goal of this intervention is to determine if contact with the research pharmacist will improve the health of the mother and/or child.
Study: NCT05981963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BMS-986196
Description: Specified dose on specified days
Study: NCT06338488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real dry needling
Description: dry needling into the muscle under ultrasound guidance.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling
Description: dry needling into the subcutaneous fatty tissue under ultrasound guidance.
Study: NCT04923230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cannabis Actions and Practices Resource for Parents
Description: The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
Study: NCT06365645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M.Bapp
Description: Please see experimental group description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App-based parenting education
Description: Please see active comparator group description.
Study: NCT05434117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval Nordic walking
Description: Participants will complete supervised exercise sessions twice weekly for 10 weeks. Exercise specialists will educate participants in proper use of walking poles and basic Nordic walking techniques and supervise the exercise training sessions. HIIT-NoW will be 45 min in duration using Nordic poles and consists of (i) a 10-min warm-up at 30-59% heart rate reserve (HRR, light-to-moderate intensity); (ii) 4 × 4 min of high-intensity work periods at 60-89% HRR (vigorous intensity) interspersed with 3 min of low-intensity work periods at 30-59% HRR (light-to-moderate intensity); and, (iii) a 10-min cooldown at 30-39% HRR (light intensity). To allow participants to acclimatize to the HIIT-NoW protocol, the training intensity will target 60-69% HRR for the first week, 70-79% HRR in the second week, and 80-89% HRR from the third week onward. If participants do not tolerate 89% HRR well, they will exercise as close to 89% HRR as possible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardiovascular rehabilitation
Description: Individuals assigned to standard CR will attend onsite exercise-based CR comprised of one onsite exercise session per week for 8-10 weeks. The onsite CR offers exercise sessions tailored to the fitness of patients and strengthening exercise.
Study: NCT05773014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Speculum Exams
Description: Same as arm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Exams
Description: Same as arm
Study: NCT05243381

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 20 ml blood test
Description: 20 ml blood test

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 20 ml blood test
Description: 20 ml blood test
Study: NCT05834036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Oral Capsule
Description: Amoxicillin 875mg every 12 hours for 7 days.
Study: NCT06163053

Intervention type: DRUG
Intervention: Immunotherapy
Description: Immune checkpoint inhibitors in approved indications
Study: NCT04723043

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation modes
Description: ventilation with pressure controlled mode in laparoscopic abdominal surgery ventilation with volume controlled mode in laparoscopic abdominal surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation modes
Description: ventilation with pressure controlled mode in laparoscopic abdominal surgery ventilation with volume controlled mode in laparoscopic abdominal surgery
Study: NCT05739435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet
Study: NCT05859633

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil/Lymphocyte Ratio in acute pancreatitis
Description: role of Neutrophil/Lymphocyte Ratio in acute pancreatitis
Study: NCT06100055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Irrigation
Description: Rectal irrigation is the introduction of warm tap water through the anal canal into the rectum to initiate defaecation.~Two alternative irrigation systems based on volume delivered exist: low-volume irrigation system depending on the manufacturer delivers approximately between 110ml to 300ml per irrigation and high-volume irrigation system delivers between 300ml to 1500ml per irrigation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Irrigation
Description: Rectal irrigation is the introduction of warm tap water through the anal canal into the rectum to initiate defaecation.~Two alternative irrigation systems based on volume delivered exist: low-volume irrigation system depending on the manufacturer delivers approximately between 110ml to 300ml per irrigation and high-volume irrigation system delivers between 300ml to 1500ml per irrigation.
Study: NCT05021003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure biofeedback
Description: : Core stabilization training with pressure biofeedback unit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core stabilization exercises
Description: : Core stabilization training without pressure biofeedback unit
Study: NCT06189404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigulixostat
Description: 300 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: 400 mg oral dose
Study: NCT06547372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention on Atopy
Description: The primary aim of this dietary intervention study is to assess the effectiveness of a dietary pattern characterized by lower saturated fats, higher wholegrains, fruit, and vegetables in reducing the severity of AD in young Singapore adults, as measured by changes in Scoring Atopic Dermatitis (SCORAD) scores, over a 2-month intervention period.
Study: NCT04998305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ-68
Description: For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of TJ-68 for three times per day before meals. It will be administered by dissolving 2.5 g of TJ-68 powder in 1 oz. of lukewarm water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ-68
Description: For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of TJ-68 for three times per day before meals. It will be administered by dissolving 2.5 g of TJ-68 powder in 1 oz. of lukewarm water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of placebo for three times per day before meals. It will be administered by dissolving 2.5 g of the placebo powder in 1 oz. of lukewarm water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of placebo for three times per day before meals. It will be administered by dissolving 2.5 g of the placebo powder in 1 oz. of lukewarm water.
Study: NCT05988164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Mask
Description: Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier.
Study: NCT05977920

Intervention type: OTHER
Group type: OTHER
Intervention: Caffeine
Description: s. description
Study: NCT06081335

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EdgeEndo x7 continuous rotation files
Description: endodontic files operating in continuous rotation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EdgeOne Fire reciprocating files
Description: endodontic files operating in reciprocating motion
Study: NCT05431634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: ESK-001
Description: Multiple doses of ESK-001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06539975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evening Primrose Oil 1000 MG
Description: Evening primrose oil 1000mg vaginally plus misoprostal for induction of labor

Intervention type: DRUG
Group type: OTHER
Intervention: Evening Primrose Oil 1000 MG
Description: Evening primrose oil 1000mg vaginally plus misoprostal for induction of labor
Study: NCT05696561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canaloplasty Device
Description: Canaloplasty
Study: NCT06389097

Intervention type: RADIATION
Intervention: Radium-223
Description: Radium-223 will be given as per standard of care or other clinical trial. It is typically administered intravenously via slow injection once every 4 weeks with a dosage of 55 kBq/kg per cycle. Patients typically receive up to six cycles unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. These will be performed at 2-4 hr, 24 hr, and 48 hr after any cycle of Radium-223. Protocol preference is for imaging with 2 cycles, ideally cycle 1 and cycle 6, but imaging with any one or two cycle(s) is acceptable.~The imaging time at each time point is approximately 30 minutes per field of view with two fields of view (1 hr total) typically collected sequentially (i.e., without repositioning the patient on the imaging table).

Intervention type: RADIATION
Intervention: 177Lu-DOTATATE
Description: 177Lu-DOTATATE to be given as Standard of Care (SOC) or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes with peptide co-infusion prior and during the infusion.~Patients will receive 4 cycles of 177Lu-DOTATATE administered approximately every 8 weeks. Treatment cycle is defined as 8 consecutive weeks (D1-D56) following a dose of 177Lu-DOTATATE. Patients receive up to four infusions of 7.4 GBq (200 mCi) every 8 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is \~ 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially.

Intervention type: RADIATION
Intervention: 177Lu-PSMA-617
Description: 177Lu-PSMA-617 will be given as per SOC or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes.~Up to 6 cycles of 177Lu- PSMA-617 will be administered approximately every 6 weeks. Treatment cycle is defined as 6 consecutive weeks (D1-D42) following a dose of 177Lu- PSMA-617. Patients will receive up to six infusions of 7.4 GBq (200 mCi) every 6 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is approximately 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially.
Study: NCT05696314

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transoral Ultrasound
Description: The oropharynx is scanned using high-frequency, small-footprint ultrasound transducers placed onto the suspected oropharynx sub-locations (e.g. tonsils or tongue base). Lidocaine spray or gel will be applied prior to scanning to reduce the gag reflex.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcervical Ultrasound
Description: Curved low-frequency ultrasound transducers will be placed on the submental region on the skin of the neck, and the tongue base will be visualized in the midline in transverse and sagittal planes. The tonsils will be visualized adjacent to the tongue base on either side in oblique transverse and oblique sagittal planes, deep to the submandibular glands.
Study: NCT05818995

Intervention type: DRUG
Intervention: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
Description: Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.
Study: NCT05542563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP) App
Description: The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
Study: NCT06283446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Cue
Description: Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Cue
Description: Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
Study: NCT05818995

Intervention type: DRUG
Intervention: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
Description: Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.

Intervention type: DRUG
Intervention: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
Description: Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.

Intervention type: DRUG
Intervention: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
Description: Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.

Intervention type: DRUG
Intervention: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
Description: Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.
Study: NCT06213194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindZone
Description: The name of the online training will be MindZone. It consists of combined game-based social cognitive and executive functions skills, and it will be presented on the training website. There is no consensus about the length of time for the training in the literature, so the average time for the training process will be used. This means that the training will last 6 weeks, 7.5 hours in total. To satisfy the training requirement, 1.15 hours (75 mins) of play will be expected from participants each week. Before each game, a brief introduction about the game will be presented and participants will get feedback about their progress. Each participant will conduct the tasks in a different random order. After 6 weeks, a post-test will be completed, and follow-up scores will be obtained after a month. All tasks were designed according to the five intervention areas: working memory, cognitive flexibility, inhibition, cognitive empathy and affective empathy based on the literature.
Study: NCT06445075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apitegromab
Description: Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same appearance and composition as apitegromab drug product but does not contain the active ingredient. Placebo will be administered every 4 weeks by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide will be administered every week by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide
Description: Glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide will be administered every week by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide will be administered every week by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirzepatide
Description: Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide will be administered every week by subcutaneous injection.
Study: NCT04877093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded placebo capsules will be provided to participants.
Study: NCT05324345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation group
Description: All patients will be guided to use the network learning platform which including details in text, pictures and videos of their individualized prehabilitation strategy after a complete assessment. Multimodal prehabilitation strategy includes conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence), physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training), nutritional suggestion and optimization (whey protein supplement), and psychological therapy. All movements can be practiced with the reference to the standard videos in the network learning platform. Patients will check the prehabilitation content daily and form their own training tasks in the network learning platform. Standardized short message interviews will be sent to patients twice a week to optimize adherence and promote timely feedback.